EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.
复制标题
DOI：
10.1136/annrheumdis-2020-219773
复制
发表时间：
2021-04
影响因子：
27.4
通讯作者：
Bijlsma JW
中科院分区：
文献类型：
--
作者：
Bijlsma JW
2019冠状病毒病疫情严重影响二零二零年生活的各个方面。这一流行病还影响到风湿性和肌肉骨骼疾病患者，并影响了对他们的护理。随着疫苗的发展，未来变得更加光明。然而，接种疫苗的可能性也提出了很多问题，特别是对于患有炎性RMD的患者和接受可能影响其免疫系统的药物治疗的患者。为了解决这些问题，EULAR成立了一个由其成员、患者、卫生专业人员和在该领域有经验的风湿病学家代表组成的工作队，负责解决相关问题。这些信息是基于目前可用的知识，意识到尚未获得有关新型疫苗在RMD患者和接受影响免疫系统药物治疗的患者中的性能的具体数据。在未来几个月，我们预计将收集更多相关信息。当您阅读此信息时，请意识到当新信息可用时，此文本将需要更新。一般而言，国家疫苗接种方案将使用几种不同类型的疫苗。目前正在使用或正在开发的专门针对COVID-19的疫苗是非活疫苗，不能给你病毒性疾病，不能将感染转移给你，也不能改变你的遗传信息。这些疫苗可以安全地用于RMD患者以及接受影响免疫系统药物的患者。其他非活疫苗已被证明对免疫抑制患者有效。更强烈地说，没有理由不向RMD患者和接受影响免疫系统药物治疗的患者提供这些疫苗。以下不同的SARS-CoV-2疫苗目前处于更先进的开发阶段，其中一些已经在不同的国家获得批准。基于mRNA（如来自Pfizer/BioNTech和来自Moderna的那些）、基于具有佐剂的蛋白质（如来自Novavax）和基于不可复制载体（如来自AstraZeneca和来自Janssen）的疫苗。
The COVID-19 pandemic has severely influenced all aspects of life in 2020. This pandemic also affected patients with rheumatic and musculoskeletal diseases (RMDs) and impacted the care given to them. With the development of vaccines, the future is becoming brighter. The possibility of vaccination however also raises a lot of questions, especially for patients with inflammatory RMDs and patients who are treated with drugs that may influence their immune system. To address these questions EULAR has formed a Task Force of representatives of its constituents, patients, health professionals and rheumatologists experienced in the field which addressed pertinent aspects. This information is based on knowledge available at this moment in time, realising that specific data about the performance of the emerging vaccines to COVID-19 in patients with RMDs and in patients treated with drugs that influence the immune system are not yet available. In the coming months we expect that more relevant information will be collected. When you read this information, please realise that this text will need to be updated when new information becomes available. In general, several different kinds of vaccines will be used in national vaccination programmes. Vaccines that are presently being used or under development specifically for COVID-19 are nonlive vaccines, that cannot give you the viral disease, that cannot transfer infection to you, nor can they change your genetic information. These vaccines can be used safely in patients with RMDs as well as in patients receiving drugs that influence the immune system. Other non-live vaccines have been proven to work for immune-suppressed patients. To say it more strongly, there is no reason to withhold these vaccines from patients with RMDs and patients treated with drugs that influence the immune system.The following different SARS-CoV-2 vaccines are presently in a more advanced stage of development and some have been approved in different countries. Vaccines based on mRNA (such as those from Pfizer/BioNTech and from Moderna), on proteins with adjuvant (such as from Novavax) and on nonreplicable vectors (such as from AstraZeneca and from Janssen).